Precigen reports full year 2024 financial results and business updates

Fda granted priority review to company's bla for prgn-2012 for the treatment of adults with recurrent respiratory papillomatosis and set pdufa target action date for august 27, 2025 results from pivotal clinical study of prgn-2012 were published in the lancet respiratory medicine prgn-2012 treatment demonstrated durable complete responses with median duration of response of two years, with some complete responders surgery-free beyond three years as of august 28, 2024 data cutoff company continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launch company ended 2024 with $97.9 million in cash, cash equivalents, and investments, extending its cash runway into 2026, beyond potential 2025 commercial launch of prgn-2012 germantown, md. , march 19, 2025 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced full year 2024 financial results and business updates.
PGEN Ratings Summary
PGEN Quant Ranking